CA2241247C - Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles - Google Patents
Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles Download PDFInfo
- Publication number
- CA2241247C CA2241247C CA002241247A CA2241247A CA2241247C CA 2241247 C CA2241247 C CA 2241247C CA 002241247 A CA002241247 A CA 002241247A CA 2241247 A CA2241247 A CA 2241247A CA 2241247 C CA2241247 C CA 2241247C
- Authority
- CA
- Canada
- Prior art keywords
- liposome
- archaeobacterium
- antigen
- archaeosomes
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 169
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 63
- 239000002671 adjuvant Substances 0.000 title claims abstract description 39
- 239000003981 vehicle Substances 0.000 title abstract description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 230000028993 immune response Effects 0.000 claims abstract description 32
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 229960005486 vaccine Drugs 0.000 claims abstract description 9
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 6
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract 5
- 150000002632 lipids Chemical class 0.000 claims description 147
- 102000036639 antigens Human genes 0.000 claims description 91
- 108091007433 antigens Proteins 0.000 claims description 91
- 239000000427 antigen Substances 0.000 claims description 88
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 72
- 235000012000 cholesterol Nutrition 0.000 claims description 34
- 241000205274 Methanosarcina mazei Species 0.000 claims description 26
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 17
- 241000202985 Methanobrevibacter smithii Species 0.000 claims description 16
- 241000204673 Thermoplasma acidophilum Species 0.000 claims description 12
- 241000205263 Methanospirillum hungatei Species 0.000 claims description 10
- 210000001539 phagocyte Anatomy 0.000 claims description 10
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 10
- 241001647363 Methanobacterium espanolae Species 0.000 claims description 8
- 241000203407 Methanocaldococcus jannaschii Species 0.000 claims description 8
- 241000204676 Methanosphaera stadtmanae Species 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 241000204946 Halobacterium salinarum Species 0.000 claims description 7
- 241000203375 Methanococcus voltae Species 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- 241000205007 Methanothrix soehngenii Species 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 229940093541 dicetylphosphate Drugs 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 8
- 239000000654 additive Substances 0.000 claims 5
- 230000000996 additive effect Effects 0.000 claims 5
- 210000001557 animal structure Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 17
- -1 vitamin E Natural products 0.000 abstract description 14
- 239000005515 coenzyme Substances 0.000 abstract description 8
- 238000010348 incorporation Methods 0.000 abstract description 7
- 230000003308 immunostimulating effect Effects 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 59
- 210000001519 tissue Anatomy 0.000 description 37
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 36
- 210000002540 macrophage Anatomy 0.000 description 36
- 229940098773 bovine serum albumin Drugs 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 29
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 238000009826 distribution Methods 0.000 description 21
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 18
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 18
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 17
- 150000002170 ethers Chemical class 0.000 description 17
- 241000203069 Archaea Species 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 230000002163 immunogen Effects 0.000 description 14
- 102000013415 peroxidase activity proteins Human genes 0.000 description 14
- 108040007629 peroxidase activity proteins Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 150000003904 phospholipids Chemical class 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 206010057249 Phagocytosis Diseases 0.000 description 10
- 230000008782 phagocytosis Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241001074903 Methanobacteria Species 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000003024 peritoneal macrophage Anatomy 0.000 description 9
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001125 extrusion Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 239000000700 radioactive tracer Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 230000000240 adjuvant effect Effects 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 230000008348 humoral response Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- ORVRQEXCVQTLMU-UHFFFAOYSA-N PGP-Me Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CCOC(COP(O)(=O)OCC(O)COP(O)(=O)OC)COCCC(C)CCCC(C)CCCC(C)CCCC(C)C ORVRQEXCVQTLMU-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000002691 unilamellar liposome Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- ISDBCJSGCHUHFI-UMZPFTBHSA-N 2,3-di-O-phytanyl-sn-glycerol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCOC[C@@H](CO)OCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C ISDBCJSGCHUHFI-UMZPFTBHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000202987 Methanobrevibacter Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ISDBCJSGCHUHFI-UHFFFAOYSA-N archaeol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CCOCC(CO)OCCC(C)CCCC(C)CCCC(C)CCCC(C)C ISDBCJSGCHUHFI-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002313 glycerolipids Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000007332 vesicle formation Effects 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000179003 Leishmania mexicana mexicana Species 0.000 description 1
- 241001054904 Methanococcus voltae PS Species 0.000 description 1
- 241001568874 Methanosarcina mazei S-6 Species 0.000 description 1
- 241000414749 Methanosphaera stadtmanae DSM 3091 Species 0.000 description 1
- 241000757088 Methanothrix soehngenii GP6 Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101000941356 Nostoc ellipsosporum Cyanovirin-N Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- VMHUDYKDOMRJOK-QUYWEVSVSA-N [(2r,7r,11r,15s,19s,22s,26s,30r,34r,38r,43r,47r,51s,55s,58s,62s,66r,70r)-38-(hydroxymethyl)-7,11,15,19,22,26,30,34,43,47,51,55,58,62,66,70-hexadecamethyl-1,4,37,40-tetraoxacyclodoheptacont-2-yl]methanol Chemical compound C[C@@H]1CCC[C@H](C)CCC[C@H](C)CC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCO[C@H](CO)COCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCO[C@H](CO)COCC[C@H](C)CCC1 VMHUDYKDOMRJOK-QUYWEVSVSA-N 0.000 description 1
- WBVHXPUFAVGIAT-UHFFFAOYSA-N [C].OCC(O)CO Chemical compound [C].OCC(O)CO WBVHXPUFAVGIAT-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- SQNZJJAZBFDUTD-UHFFFAOYSA-N durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US872495P | 1995-12-15 | 1995-12-15 | |
| US60/008,724 | 1995-12-15 | ||
| PCT/CA1996/000835 WO1997022333A1 (en) | 1995-12-15 | 1996-12-13 | Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2241247A1 CA2241247A1 (en) | 1997-06-26 |
| CA2241247C true CA2241247C (en) | 2004-01-20 |
Family
ID=21733297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002241247A Expired - Fee Related CA2241247C (en) | 1995-12-15 | 1996-12-13 | Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6132789A (enExample) |
| EP (1) | EP0869773B1 (enExample) |
| JP (1) | JP2000502087A (enExample) |
| CA (1) | CA2241247C (enExample) |
| DE (1) | DE69631970T2 (enExample) |
| WO (1) | WO1997022333A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7861166B1 (en) | 1993-12-02 | 2010-12-28 | Discovery Patent Holding, Llc | Resizing document pages to fit available hardware screens |
| US7865567B1 (en) | 1993-12-02 | 2011-01-04 | Discovery Patent Holdings, Llc | Virtual on-demand electronic book |
| ES2154560B1 (es) * | 1998-09-16 | 2001-12-01 | Lipotec Sa | Composicion a base de derivados de cromanos y su uso para reducir quimicamente las reacciones oxidativas o inducidas por radicales libres. |
| US6200550B1 (en) * | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
| ES2320971T3 (es) * | 1999-10-12 | 2009-06-01 | National Research Council Of Canada | Arqueosomas como adjuvantes y vehiculos para vacunas acelulares para inducir respuestas de linfocitos t cototoxicos. |
| WO2002009678A2 (en) | 2000-07-31 | 2002-02-07 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
| US6897196B1 (en) * | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
| AR036316A1 (es) * | 2002-08-29 | 2004-08-25 | Monte Verde S A | Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion |
| US7179484B2 (en) * | 2002-11-06 | 2007-02-20 | Azaya Therapeutics, Inc. | Protein-stabilized liposomal formulations of pharmaceutical agents |
| CA2519927A1 (en) * | 2003-04-02 | 2004-10-21 | Pharmachem Laboratories, Inc. | Novel probiotic compositions and methods of using the same |
| US8252322B2 (en) * | 2003-06-03 | 2012-08-28 | Corn Products Development, Inc. | Delivery system with increased bioavailability |
| US20050158329A1 (en) * | 2004-01-21 | 2005-07-21 | Ghosh Swapan K. | Novel phytol derived immunoadjuvants and their use in vaccine formulations |
| FR2878846B1 (fr) | 2004-12-07 | 2007-02-23 | Enscr | Composes analogues de lipides membranaires d'archaebacteries et compositions liposomiales integrant de tel composes |
| EP1861490A4 (en) * | 2005-03-23 | 2010-11-17 | Univ St Louis | USE OF ARCHAEA FOR MODULATING NUTRITIONAL FUNCTIONALITY OF GASTROINTESTINAL BIOZOOSIS |
| EP1999137B1 (en) * | 2006-03-30 | 2016-03-30 | National Research Council Of Canada | Synthetic archaeal glycolipid adjuvants |
| TW200833709A (en) | 2006-12-15 | 2008-08-16 | Ca Nat Research Council | Archaeal polar lipid aggregates for administration to animals |
| GB2463801B (en) * | 2007-03-20 | 2011-07-13 | Univ Plymouth | Isoprenoid compounds, their isolation and use |
| JPWO2009004900A1 (ja) * | 2007-06-29 | 2010-08-26 | 学校法人 城西大学 | ユビキノン含有免疫アジュバント |
| EP2227085A4 (en) * | 2007-12-06 | 2013-10-09 | Berg Pharma Llc | INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY |
| CN101368214B (zh) * | 2008-09-24 | 2010-09-15 | 上海大学 | 用于古细菌多样性分析的针对16S rRNA基因的引物 |
| KR101907411B1 (ko) | 2010-03-12 | 2018-10-12 | 베르그 엘엘씨 | 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법 |
| CN107095863A (zh) | 2011-06-17 | 2017-08-29 | 博格有限责任公司 | 可吸入药物组合物 |
| MX347400B (es) * | 2012-06-29 | 2017-04-18 | Univ Nac Autónoma De México | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. |
| EP2968147A4 (en) * | 2013-03-15 | 2017-02-22 | The Penn State Research Foundation | Acid stable liposomal compositions |
| JP6263609B2 (ja) * | 2014-04-30 | 2018-01-17 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| SI3138555T1 (sl) | 2014-04-30 | 2021-06-30 | Fujifilm Corporation | Liposomski sestavek in proizvodni postopek zanj |
| CA2954740C (en) * | 2014-07-11 | 2022-10-18 | National Research Council Of Canada | Sulfated-glycolipids as adjuvants for vaccines |
| EP3158992A1 (en) * | 2015-10-21 | 2017-04-26 | Universität Heidelberg | Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules |
| ES2773763T3 (es) * | 2015-10-21 | 2020-07-14 | Univ Heidelberg | Formulación liposomal novedosa para la administración hepática oral de fármacos |
| AU2019288048B2 (en) | 2018-06-20 | 2022-08-11 | Fujifilm Corporation | Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade |
| EP3628309A1 (en) | 2018-09-28 | 2020-04-01 | Universität Heidelberg | Method of making oral dosage forms |
| EP3708151A1 (en) * | 2019-03-15 | 2020-09-16 | Technische Universität Wien | Method for producing a composition comprising archaeal lipids from a sulfolobus cell culture |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS588010A (ja) * | 1981-07-08 | 1983-01-18 | Eisai Co Ltd | ユビデカレノン含有リポソ−ム |
| JPS58201711A (ja) * | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | ユビデカレノン含有リポソ−ム被覆体 |
| JPS6058915A (ja) * | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| FR2591105B1 (fr) * | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide. |
| US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
| JPH02295917A (ja) * | 1989-05-10 | 1990-12-06 | Terumo Corp | 内包物の酸化を抑制したリポソームおよびその製法 |
| EP0455386B1 (en) * | 1990-04-21 | 1993-12-29 | United Biscuits (Uk) Limited | Fat based food products |
| JP3132039B2 (ja) * | 1991-02-25 | 2001-02-05 | 大正製薬株式会社 | ビタミンａ含有リポソーム水懸濁液 |
| JPH04300838A (ja) * | 1991-03-28 | 1992-10-23 | Terumo Corp | 人工赤血球および人工赤血球懸濁液 |
| DE69221496T2 (de) * | 1991-10-23 | 1997-12-11 | National Research Council Of Canada, Ottawa, Ontario | Formierung von stabilen Liposomen aus Lipidextrakten von Archaeobakterien. |
| DE59307395D1 (de) * | 1992-07-08 | 1997-10-23 | Dianorm G Maierhofer Gmbh | Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels |
-
1996
- 1996-12-13 US US09/077,956 patent/US6132789A/en not_active Expired - Lifetime
- 1996-12-13 EP EP96940963A patent/EP0869773B1/en not_active Expired - Lifetime
- 1996-12-13 JP JP9522375A patent/JP2000502087A/ja not_active Ceased
- 1996-12-13 DE DE69631970T patent/DE69631970T2/de not_active Expired - Fee Related
- 1996-12-13 WO PCT/CA1996/000835 patent/WO1997022333A1/en not_active Ceased
- 1996-12-13 CA CA002241247A patent/CA2241247C/en not_active Expired - Fee Related
-
2000
- 2000-07-06 US US09/612,618 patent/US6403117B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000502087A (ja) | 2000-02-22 |
| WO1997022333A1 (en) | 1997-06-26 |
| DE69631970D1 (de) | 2004-04-29 |
| DE69631970T2 (de) | 2005-04-14 |
| EP0869773B1 (en) | 2004-03-24 |
| US6403117B1 (en) | 2002-06-11 |
| CA2241247A1 (en) | 1997-06-26 |
| EP0869773A1 (en) | 1998-10-14 |
| US6132789A (en) | 2000-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6132789A (en) | Archaeosomes, archaeosomes containing coenzyme Q10, and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles | |
| AU627226B2 (en) | Influenza vaccine and novel adjuvants | |
| US5916588A (en) | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use | |
| Gregoriadis | Immunological adjuvants: a role for liposomes | |
| Benvegnu et al. | New generation of liposomes called archaeosomes based on natural or synthetic archaeal lipids as innovative formulations for drug delivery | |
| US6090406A (en) | Potentiation of immune responses with liposomal adjuvants | |
| JP2828391B2 (ja) | オリゴ糖を表面に有するリポソーム | |
| Storm et al. | Liposomes: quo vadis? | |
| Frezard | Liposomes: from biophysics to the design of peptide vaccines | |
| US5100662A (en) | Steroidal liposomes exhibiting enhanced stability | |
| US10434167B2 (en) | Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin | |
| US5026557A (en) | Adjuvant composition | |
| US4971803A (en) | Lamellar vesicles formed of cholesterol derivatives | |
| US4117113A (en) | Immunological preparations | |
| JPH06504759A (ja) | リポソーム含有ワクチン組成物 | |
| US20170072033A1 (en) | Liposomal compositions for mucosal delivery | |
| WO1993017702A1 (fr) | Vaccin oral | |
| US8871252B2 (en) | pH-responsive liposome | |
| Tolson et al. | Uptake of archaeobacterial liposomes and conventional liposomes by phagocytic cells | |
| Davis et al. | Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators | |
| US5897873A (en) | Affinity associated vaccine | |
| JPH07108166A (ja) | リポソーム | |
| Makabi-Panzu et al. | Coenzyme Q10 in vesicles composed of archaeal ether lipids or conventional lipids enhances the immuno-adjuvanticity to encapsulated protein | |
| JPH05339169A (ja) | 経口ワクチン | |
| Uemura et al. | Induction of immune responses against glycosphingolipid antigens: Comparison of antibody responses in mice immunized with antigen associated with liposomes prepared from various phospholipids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |